Selpercatinib (Retsevmo®) for advanced RET-mutant medullary thyroid cancer. HTA ID: 21020a

Assessment Status Awaiting HTA submission from Applicant
HTA ID 21020a
Drug Selpercatinib
Brand Retsevmo®
Indication Is indicated for adult and adolescent patients, 12 years and older, with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib.  
Assessment Process
Rapid review commissioned 08/06/2021
Rapid review completed 07/07/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of selpercatinib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 22/07/2021
Pre-submission consultation with Applicant 08/11/2021

The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.